OcuNexus Therapeutics
| Site | |
|---|---|
| Stage of funding: | Current |
| Therapeutic group: | Ophthalmology |
| Type: | Drug |
Description
OcuNexus Therapeutics, Inc. is a clinical stage biopharmaceutical company developing highly differentiated drug candidates based upon novel connexin43 hemichannel modulation mechanisms. OcuNexus has developed potential upstream treatments for multiple front- and back-of-the-eye diseases and disorders with high unmet needs. The company's technologies are expected to be transferable to other acute and chronic disease indications involving pathological connexin43 hemichannel overexpression and assembly of inflammasomes.
OcuNexus main asset, NEXAGON, was outlicensed to Eyevance Pharmaceuticals, Inc. (now Amber Ophthalmics) in 2018. A positive clinical data from the ongoing Phase2/3 study by Amber (2023) provides good expectations for bringing of NEXAGON to the market.
The company is based in San Diego area, CA, US. More details at: http://ocunexus.com
Portfolio companies news
-
Clearside Biomedical, Inc. (“Clearside”), (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that data from PEACHTREE, its pivotal Phase 3 trial of suprachoroidal CLS-TA in patients with macular edema associated with non-infectious uveitis, will be shared as a late-breaking oral presentation during the 2018 annual meeting of the American Society of Retina Specialists , July 20-25 in Vancouver, Canada .
-
11 July 2018
Clearside Biomedical Appoints Carol Hoang as Vice President, Medical Affairs
-
10 July 2018
Blood Test Predicts Treatment Response and Survival for Patients with Metastatic Prostate Cancer
-
21 June 2018
Marinus Pharmaceuticals to Be Added to the Russell 2000 and Russell 3000 Index